250 related articles for article (PubMed ID: 22688893)
1. Differential secretome analysis reveals CST6 as a suppressor of breast cancer bone metastasis.
Jin L; Zhang Y; Li H; Yao L; Fu D; Yao X; Xu LX; Hu X; Hu G
Cell Res; 2012 Sep; 22(9):1356-73. PubMed ID: 22688893
[TBL] [Abstract][Full Text] [Related]
2. CST6 protein and peptides inhibit breast cancer bone metastasis by suppressing CTSB activity and osteoclastogenesis.
Li X; Liang Y; Lian C; Peng F; Xiao Y; He Y; Ma C; Wang Y; Zhang P; Deng Y; Su Y; Luo C; Kong X; Yang Q; Liu T; Hu G
Theranostics; 2021; 11(20):9821-9832. PubMed ID: 34815788
[No Abstract] [Full Text] [Related]
3. TBX2 represses CST6 resulting in uncontrolled legumain activity to sustain breast cancer proliferation: a novel cancer-selective target pathway with therapeutic opportunities.
D'Costa ZC; Higgins C; Ong CW; Irwin GW; Boyle D; McArt DG; McCloskey K; Buckley NE; Crawford NT; Thiagarajan L; Murray JT; Kennedy RD; Mulligan KA; Harkin DP; Waugh DJ; Scott CJ; Salto-Tellez M; Williams R; Mullan PB
Oncotarget; 2014 Mar; 5(6):1609-20. PubMed ID: 24742492
[TBL] [Abstract][Full Text] [Related]
4. Frequent loss of cystatin E/M expression implicated in the progression of prostate cancer.
Pulukuri SM; Gorantla B; Knost JA; Rao JS
Oncogene; 2009 Aug; 28(31):2829-38. PubMed ID: 19503093
[TBL] [Abstract][Full Text] [Related]
5. The candidate tumor suppressor CST6 alters the gene expression profile of human breast carcinoma cells: down-regulation of the potent mitogenic, motogenic, and angiogenic factor autotaxin.
Song J; Jie C; Polk P; Shridhar R; Clair T; Zhang J; Yin L; Keppler D
Biochem Biophys Res Commun; 2006 Feb; 340(1):175-82. PubMed ID: 16356477
[TBL] [Abstract][Full Text] [Related]
6. The ubiquitin E3 ligase WWP1 decreases CXCL12-mediated MDA231 breast cancer cell migration and bone metastasis.
Subik K; Shu L; Wu C; Liang Q; Hicks D; Boyce B; Schiffhauer L; Chen D; Chen C; Tang P; Xing L
Bone; 2012 Apr; 50(4):813-23. PubMed ID: 22266093
[TBL] [Abstract][Full Text] [Related]
7. Correlation of Cystatin E/M with Clinicopathological Features and Prognosis in Triple-Negative Breast Cancer.
Li Q; Zheng ZC; Ni CJ; Jin WX; Jin YX; Chen Y; Zhang XH; Chen ED; Cai YF
Ann Clin Lab Sci; 2018 Jan; 48(1):40-44. PubMed ID: 29530995
[TBL] [Abstract][Full Text] [Related]
8. Methylation-dependent silencing of CST6 in primary human breast tumors and metastatic lesions.
Rivenbark AG; Livasy CA; Boyd CE; Keppler D; Coleman WB
Exp Mol Pathol; 2007 Oct; 83(2):188-97. PubMed ID: 17540367
[TBL] [Abstract][Full Text] [Related]
9. The hypoxic cancer secretome induces pre-metastatic bone lesions through lysyl oxidase.
Cox TR; Rumney RMH; Schoof EM; Perryman L; Høye AM; Agrawal A; Bird D; Latif NA; Forrest H; Evans HR; Huggins ID; Lang G; Linding R; Gartland A; Erler JT
Nature; 2015 Jun; 522(7554):106-110. PubMed ID: 26017313
[TBL] [Abstract][Full Text] [Related]
10. Invasion suppressor cystatin E/M (CST6): high-level cell type-specific expression in normal brain and epigenetic silencing in gliomas.
Qiu J; Ai L; Ramachandran C; Yao B; Gopalakrishnan S; Fields CR; Delmas AL; Dyer LM; Melnick SJ; Yachnis AT; Schwartz PH; Fine HA; Brown KD; Robertson KD
Lab Invest; 2008 Sep; 88(9):910-25. PubMed ID: 18607344
[TBL] [Abstract][Full Text] [Related]
11. CST6 promoter methylation in circulating cell-free DNA of breast cancer patients.
Chimonidou M; Tzitzira A; Strati A; Sotiropoulou G; Sfikas C; Malamos N; Georgoulias V; Lianidou E
Clin Biochem; 2013 Feb; 46(3):235-40. PubMed ID: 23006792
[TBL] [Abstract][Full Text] [Related]
12. Methylation of cystatin M promoter is associated with unfavorable prognosis in operable breast cancer.
Kioulafa M; Balkouranidou I; Sotiropoulou G; Kaklamanis L; Mavroudis D; Georgoulias V; Lianidou ES
Int J Cancer; 2009 Dec; 125(12):2887-92. PubMed ID: 19551853
[TBL] [Abstract][Full Text] [Related]
13. Gold clusters prevent breast cancer bone metastasis by suppressing tumor-induced osteoclastogenesis.
Zhang Z; Yao Y; Yuan Q; Lu C; Zhang X; Yuan J; Hou K; Zhang C; Du Z; Gao X; Chen X
Theranostics; 2020; 10(9):4042-4055. PubMed ID: 32226538
[No Abstract] [Full Text] [Related]
14. Up-regulation of bone marrow stromal protein 2 (BST2) in breast cancer with bone metastasis.
Cai D; Cao J; Li Z; Zheng X; Yao Y; Li W; Yuan Z
BMC Cancer; 2009 Apr; 9():102. PubMed ID: 19338666
[TBL] [Abstract][Full Text] [Related]
15. Comparative membrane proteomics analyses of breast cancer cell lines to understand the molecular mechanism of breast cancer brain metastasis.
Peng W; Zhang Y; Zhu R; Mechref Y
Electrophoresis; 2017 Sep; 38(17):2124-2134. PubMed ID: 28523741
[TBL] [Abstract][Full Text] [Related]
16. Long non-coding RNA BANCR indicates poor prognosis for breast cancer and promotes cell proliferation and invasion.
Lou KX; Li ZH; Wang P; Liu Z; Chen Y; Wang XL; Cui HX
Eur Rev Med Pharmacol Sci; 2018 Mar; 22(5):1358-1365. PubMed ID: 29565494
[TBL] [Abstract][Full Text] [Related]
17. Proteomics approach to identify novel metastatic bone markers from the secretome of PC-3 prostate cancer cells.
Sung E; Kwon OK; Lee JM; Lee S
Electrophoresis; 2017 Oct; 38(20):2638-2645. PubMed ID: 28627741
[TBL] [Abstract][Full Text] [Related]
18. Pathogenic role of connective tissue growth factor (CTGF/CCN2) in osteolytic metastasis of breast cancer.
Shimo T; Kubota S; Yoshioka N; Ibaragi S; Isowa S; Eguchi T; Sasaki A; Takigawa M
J Bone Miner Res; 2006 Jul; 21(7):1045-59. PubMed ID: 16813525
[TBL] [Abstract][Full Text] [Related]
19. Global secretome analysis identifies novel mediators of bone metastasis.
Blanco MA; LeRoy G; Khan Z; Alečković M; Zee BM; Garcia BA; Kang Y
Cell Res; 2012 Sep; 22(9):1339-55. PubMed ID: 22688892
[TBL] [Abstract][Full Text] [Related]
20. Insulin like growth factor binding protein-7 reduces growth of human breast cancer cells and xenografted tumors.
Amemiya Y; Yang W; Benatar T; Nofech-Mozes S; Yee A; Kahn H; Holloway C; Seth A
Breast Cancer Res Treat; 2011 Apr; 126(2):373-84. PubMed ID: 20464481
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
